Cannabis Use Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Cannabis as a Schedule I drug is classified by the FDA. The usage of cannabis exhibits variations across different demographic groups. Tetrahydrocannabinol (THC) serves as the primary compound responsible for the reinforcing effects of marijuana. Although the striatal dopamine system typically plays a role in substances of abuse, such as alcohol and opioids, current meta-analyses lack sufficient evidence to support a similar conclusion regarding cannabis. The Diagnostic and Statistical Manual of Mental Disorders (DSM–5) has updated the criteria for cannabis use disorder, delineating nine pathological patterns categorized under impaired control, social impairment, risky behavior, or physiological adaptation. It is focused on cannabis misuse and its associated elements, including states of intoxication, withdrawal, and cannabis use disorder. Moreover, dopamine receptors may not be directly involved. The primary objective is to enhance the overall functioning of the individual, which is a complex, multifaceted process. As cannabis strains become increasingly potent and accessible, there is a heightened risk of experiencing more frequent and severe adverse reactions. Treatment targeting specific symptoms may include the use of alpha-2-adrenergic agonists or beta-blockers to address tachycardia, benzodiazepines to manage panic attacks, off-label administration of first-generation antihistamines for alleviating anxiety and restlessness, and neuroleptics for addressing psychosis. Currently, no medication is approved by the FDA specifically for treating cannabis use disorder.
Thelansis’s “Cannabis Use Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cannabis Use Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cannabis Use Disorder across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Cannabis Use Disorder Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment